HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ADGRL1
adhesion G protein-coupled receptor L1
Chromosome 19 Β· 19p13.12
NCBI Gene: 22859Ensembl: ENSG00000072071.18HGNC: HGNC:20973UniProt: O94910
45PubMed Papers
1Diseases
0Drugs
27Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedReceptor
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingneuron projectionsynapselatrotoxin receptor activityDevelopmental delay, behavioral abnormalities, and neuropsychiatric disorders
✦AI Summary

ADGRL1 (adhesion G protein-coupled receptor L1) is an adhesion GPCR functioning as a calcium-independent, high-affinity receptor for alpha-latrotoxin and TENM2, mediating synaptic cell-cell contact and postsynaptic specialization 1. The receptor acts as a signaling platform connecting trans-cellular interactions to cellular responses through G protein activation and recruitment of postsynaptic scaffolds, with its function regulated by extensive alternative splicing 2. ADGRL1 haploinsufficiency causes a variable spectrum of neurodevelopmental disorders in humans, including developmental delay, intellectual disability, autism spectrum disorder, attention deficit hyperactivity disorder, and epilepsy 3. In heterozygous carriers, ADGRL1 variants show faulty ligand-induced calcium signaling, while Adgrl1-knockout mice exhibit stereotypic behaviors, sexual dysfunction, altered locomotion, and increased spontaneous neurotransmitter exocytosis 3. Beyond neuronal function, ADGRL1 serves as a glucose receptor in the hypothalamus, binding glucose to regulate energy and glucose homeostasis in a sex-dependent manner; dysfunction increases obesity risk and impairs glucose sensing 45. ADGRL1 variants associate with developmental epileptic encephalopathy and genetic epilepsy with febrile seizures plus, with variant location predicting severity 6. The protein's upregulation in certain cancers correlates with poor prognosis, suggesting potential as an immunotherapeutic target 78.

Sources cited
1
ADGRL1 nomenclature and classification as adhesion GPCR family member
PMID: 25713288
2
ADGRL1 haploinsufficiency causes neurodevelopmental disorders, faulty calcium signaling, and behavioral abnormalities in mice and humans
PMID: 35907405
3
ADGRL1 signaling mechanisms, alternative splicing, binding to Teneurins and FLRTs, and postsynaptic organization function
PMID: 40127755
4
ADGRL1 functions as glucose receptor in hypothalamus regulating energy and glucose homeostasis
PMID: 37712955
5
ADGRL1 dysfunction increases obesity risk and dysregulates glucose homeostasis
PMID: 38664368
6
ADGRL1 variants associate with epilepsy ranging from genetic epilepsy with febrile seizures plus to developmental epileptic encephalopathy
PMID: 38927006
7
ADGRL1 upregulation in uterine endometrial cancer correlates with poor prognosis
PMID: 35413679
8
ADGRL1 upregulation in breast cancer correlates with poor overall survival
PMID: 38834774
Disease Associationsβ“˜1
Developmental delay, behavioral abnormalities, and neuropsychiatric disordersUniProt
Pathogenic Variants27
NM_014921.5(ADGRL1):c.2150-1G>CLikely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2026
NM_014921.5(ADGRL1):c.283_284del (p.Arg95fs)Pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2026β†’ Residue 95
NM_014921.5(ADGRL1):c.3477_3480del (p.Phe1160fs)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2025β†’ Residue 1160
NM_014921.5(ADGRL1):c.1683C>G (p.Tyr561Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 561
NM_014921.5(ADGRL1):c.812G>A (p.Gly271Glu)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2025β†’ Residue 271
NM_014921.5(ADGRL1):c.1507C>T (p.Arg503Ter)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2025β†’ Residue 503
NM_014921.5(ADGRL1):c.2634C>A (p.Cys878Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 878
NM_014921.5(ADGRL1):c.245A>G (p.Gln82Arg)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2025β†’ Residue 82
NM_014921.5(ADGRL1):c.446_447del (p.His149fs)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2024β†’ Residue 149
NM_014921.5(ADGRL1):c.70+2T>CLikely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2024
NM_014921.5(ADGRL1):c.1367_1383dup (p.Pro462fs)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2024β†’ Residue 462
NM_014921.5(ADGRL1):c.2567C>A (p.Ser856Ter)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 856
NM_014921.5(ADGRL1):c.3414_3415del (p.Gly1139fs)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 1139
NM_014921.5(ADGRL1):c.614_615insGTTG (p.Val206fs)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 206
NM_014921.5(ADGRL1):c.2270_2271del (p.Val757fs)Pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2024β†’ Residue 757
NM_014921.5(ADGRL1):c.3256dup (p.Val1086fs)Pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2023β†’ Residue 1086
NM_014921.5(ADGRL1):c.371_372dup (p.Gln125fs)Likely pathogenic
Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†2023β†’ Residue 125
NM_014921.5(ADGRL1):c.1432C>T (p.Arg478Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 478
NM_014921.5(ADGRL1):c.3440T>C (p.Met1147Thr)Pathogenic
Global developmental delay|Developmental delay, behavioral abnormalities, and neuropsychiatric disorders
β˜…β˜†β˜†β˜†β†’ Residue 1147
NM_014921.5(ADGRL1):c.1022A>G (p.Tyr341Cys)Likely pathogenic
Intellectual disability;Global developmental delay
β˜…β˜†β˜†β˜†β†’ Residue 341
View on ClinVar β†—
Related Genes
MS4A18Shared pathway100%MS4A13Shared pathway100%MS4A10Shared pathway100%MS4A6EShared pathway100%MS4A15Shared pathway100%MS4A14Shared pathway100%
Tissue Expression

No tissue expression data available for this gene.

Gene Interaction Network
Click a node to explore
ADGRL1MS4A18MS4A13MS4A10MS4A6EMS4A15MS4A14
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt O94910
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.30Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.22 [0.17–0.30]
RankingsWhere ADGRL1 stands among ~20K protein-coding genes
  • #9,409of 20,598
    Most Researched45
  • #1,915of 5,498
    Most Pathogenic Variants27
  • #1,170of 17,882
    Most Constrained (LOEUF)0.30 Β· top 10%
Genes detectedADGRL1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors.
PMID: 25713288
Pharmacol Rev Β· 2015
1.00
2
ADGRL1 haploinsufficiency causes a variable spectrum of neurodevelopmental disorders in humans and alters synaptic activity and behavior in a mouse model.
PMID: 35907405
Am J Hum Genet Β· 2022
0.90
3
Signaling by latrophilin adhesion-GPCRs in synapse assembly.
PMID: 40127755
Neuroscience Β· 2025
0.80
4
Dysfunction of the adhesion G protein-coupled receptor latrophilin 1 (ADGRL1/LPHN1) increases the risk of obesity.
PMID: 38664368
Signal Transduct Target Ther Β· 2024
0.70
5
ADGRL1 variants: From developmental and epileptic encephalopathy to genetic epilepsy with febrile seizures plus.
PMID: 38927006
Dev Med Child Neurol Β· 2025
0.60